Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856189 · ClinicalTrials.gov registry record · Phase 1
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 1 study, sponsored by Mamta Parikh.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04856189 is a Phase 1 study that was terminated before completion, run by Mamta Parikh. The registered enrollment target is 4 participants.
The verdict
NCT04856189, a Phase 1 study, was terminated before completion, sponsored by Mamta Parikh.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase Ib/II trial finds the best dose of selinexor and its effect with pembrolizumab in treating patients with urothelial carcinoma that are not eligible to receive the chemotherapy drug cisplatin, or have been given cisplatin and the cancer has gotten worse. Patients must also have urothelial carcinoma that has spread locally, near where it started (locally advanced), or has spread to other parts of the body (metastatic). Selinexor may stop the growth of tumor cells by blocking a protein, called XPO1, that is needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving selinexor and pembrolizumab may kill more tumor cells.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04856189
The ClinicalTrials.gov registry entry for NCT04856189 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mamta Parikh, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04856189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04856189 about?
NCT04856189 is a clinical study titled "Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma". This phase Ib/II trial finds the best dose of selinexor and its effect with pembrolizumab in treating patients with urothelial carcinoma that are not eligible to receive the chemotherapy drug cisplatin, or have been given cisplatin and the cancer has gotten worse. Patients must also have urothelial ...
What is the current status of trial NCT04856189?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-04-08. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT04856189?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Selinexor (DRUG).
Who is sponsoring clinical trial NCT04856189?
This trial is sponsored by Mamta Parikh, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.